Orexo to present at 2015 Nordic Life Sciences Conference

Uppsala, Sweden – April 22, 2015 – Orexo AB (Nasdaq Stockholm: ORX and US OTCQX:
ORXOY) today announced that Nikolaj Sørensen, President and Chief Executive
Officer, will present a company overview at the 2015 Nordic Life Sciences
Conference hosted by the Trout Group and Pareto Securities in New York, NY, on
Monday, April 27, 2015 at 10:00 a.m. Eastern Time. Orexo is a specialty pharma
company commercializing Zubsolv® (buprenorphine/naloxone) sublingual tablet
(CIII) for maintenance treatment of opioid dependence in the United States and
developing improved treatments using proprietary drug delivery technologies in
Sweden.

For information about the conference, please visit
www.troutgroup.com/page/nordic. The presentation will be made available at
www.orexo.com following the conference.

About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for maintenance treatment of opioid dependence in the US.
Zubsolv® is an advanced formulation of buprenorphine and naloxone using Orexo’s
unique knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden.

For information about Orexo and Zubsolv, please visit www.orexo.com and
www.zubsolv.com.

Contact Information:
Nikolaj Sørensen, President and Chief Executive Officer of Orexo
Tel: +46 (0)70-350 78 88, E-mail: ir@orexo.com

Rhonda Chiger (U.S. investors)
Rx Communications Group, LLC
Tel: 917-322-2569, E-mail: rchiger@rxir.com

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act. The information was submitted for publication
at 6:15 pm CET on April 22, 2015.